Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 715790, 11 pages
Review Article

Sulfotanshinone Sodium Injection for Unstable Angina Pectoris: A Systematic Review of Randomized Controlled Trials

1Department of Clinical Pharmacy & Pharmacy Administration, West China Pharmacy School, Sichuan University, No. 17 Section 3 Renmin Nanlu, Chengdu, Sichuan 610041, China
2Department of Acupuncture & Chinese Medicine, Canadian College of Acupuncture and Oriental Medicine, 551 Chatham Street, Victoria, BC, Canada V8T 1E1
3Center for Health Research North West, Kaiser Permanente, 5025 Southeast 28th Avenue, Portland, OR 97202, USA
4Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada L8S 4L8

Received 20 October 2011; Revised 5 January 2012; Accepted 5 January 2012

Academic Editor: Myeong Soo Lee

Copyright © 2012 Xuelan Qiu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To assess the effect of sulfotanshinone sodium injection for unstable angina. Methods. We searched for published and unpublished studies up to June 2011. We included randomized controlled trials that confoundedly addressed the effect of sulfotanshinone sodium injection in the treatment of unstable angina. Results. Twenty-five studies involving 2,377 people were included. There was no evidence that sulfotanshinone sodium alone had better or worse effects to routine western medicine treatments in improving clinical symptoms (RR 1.00, 95% CI 0.90 to 1.11) and ECG (RR 0.97, 95% CI 0.87 to 1.09). However, there was evidence that sulfotanshinone sodium combined with western medications was a better treatment option than western medications alone in improving clinical symptoms (RR 1.28, 95% CI 1.23 to 1.3), ECG (RR 1.26, 95% CI 1.18 to 1.35), C-reaction protein (mean difference 2.10, 95% CI 1.63 to 2.58), and IL-6 (mean difference −3.85, 95% CI −4.10 to −3.60). There was no difference between sulfotanshinone sodium plus western medications and western medications alone affecting mortality (RR 0.50, 95% CI 0.02 to 12.13). Conclusion. Compared with western medications alone, sulfotanshinone sodium combined with western medications may provide more benefits for patients with unstable angina. Further large-scale high-quality trials are warranted.